NPM1 and acute myeloid leukemia: In parallel, ziftomenib achieved clinically meaningful complete remission with hematologic recovery (CR/CRh) rates of 30% with molecular clearance in relapsed/refractory (R/R) NPM1-mutated AML, with a safety profile marked by differentiation syndrome (DS: ∼15% incidence), low-grade gastrointestinal events, and manageable myelosuppression (Wang E. S. et al., 2024).